secwatch.observer — SEC 8-K summary
======================================

Issuer:     Annovis Bio, Inc. (ANVS)
CIK:        0001477845
Form:       8-K
Filed at:   2024-04-26T23:59:59+00:00
Accession:  0001104659-24-052471
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Annovis Bio enters equity line with Keystone Capital for up to 2.05M shares
---------------------------------------------------------------------------

- Company may sell up to 2,051,428 shares at market price, subject to 19.99% cap unless at-market.
- Initial commitment shares: 10,181 delivered at signing; additional shares on days 90 and 180.
- Proceeds will be used for working capital and general corporate purposes.
- Investor Keystone Capital cannot engage in short sales or hedging during agreement term.
- Fixed purchase limit: lower of 25,000 shares or $250,000; VWAP aggregate cap $10M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1477845/000110465924052471/0001104659-24-052471-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1477845/000110465924052471/tm2412796d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-052471

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer